New cancer clinical trial: G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Published on: March 07, 2018 at 12:00PM
Conditions:   Carcinoma, Non-Small-Cell Lung;   Lung Cancer;   Non-small Cell Lung Cancer
Interventions:   Drug: G1T38;   Drug: Osimertinib
Sponsor:   G1 Therapeutics, Inc.
Not yet recruiting
http://ift.tt/2FxINuz